Cognition Therapeutics

OverviewSuggest Edit

Cognition Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting diseases and disorders of the central nervous system and retina. Its main product candidate is CT1812, an orally delivered small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. The company also intends to develop other product candidates in the area of synucleinopathies.
TypePublic
Founded2007
HQPittsburgh, PA, US
Websitecogrx.com

Latest Updates

Employees (est.) (Oct 2021)18
Share Price (Nov 2021)$11.7(-3%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cognition Therapeutics

Lisa Ricciardi

Lisa Ricciardi

Chief Executive Officer, Director
James M. O'Brien

James M. O'Brien

Chief Financial Officer
Brett P. Monia

Brett P. Monia

Director
Peggy Wallace

Peggy Wallace

Director
Mark H. Breedlove

Mark H. Breedlove

Director
Aaron Fletcher

Aaron Fletcher

Director
Show more

Cognition Therapeutics Office Locations

Cognition Therapeutics has offices in Pittsburgh and Harrison
Pittsburgh, PA, US (HQ)
2403 Sidney Street
Harrison, NY, US
2500 Westchester
Show all (2)

Cognition Therapeutics Financials and Metrics

Cognition Therapeutics Revenue

Market capitalization (12-Nov-2021)

254.2m

Closing stock price (12-Nov-2021)

11.7
Cognition Therapeutics's current market capitalization is $254.2 m.
Show all financial metrics

Cognition Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Cognition Therapeutics Online and Social Media Presence

Embed Graph

Cognition Therapeutics News and Updates

Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indications Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indications

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central ner…

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central ner…

Cognition Therapeutics raised more than $45 million after IPO priced in the middle of the expected range

Cognition Therapeutics Inc.'s stock is set to start trading Friday, after the New York-based biopharmaceutical company targeting treatments for central nervous systems disorders said its upsized initial public offering priced at $12 a share, in the middle of the expected range of between $11 and $1…

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and…

Cognition Therapeutics Announces Launch of its Initial Public Offering

PURCHASE, N.Y., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and…
Show more

Cognition Therapeutics Blogs

Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board

Cognition Therapeutics, Inc. announced that the board of directors has elected Jack A. Khattar, founder and CEO of Supernus Pharmaceuticals, chairman of the board. The post Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board appeared first on Cognition Therapeutics, Inc.…

Anthony O. Caggiano, M.D., Ph.D.

Dr. Caggiano is a broad-based therapeutic development executive with experience across a range of disease indications, including neurological disorders. Earlier in his career, Dr. Caggiano was acting president and chief medical officer of Constant Pharmaceuticals and Aeromics, Inc., clinical-stage c…

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease

PITTSBURGH, October 19, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-4…

Cognition Therapeutics Expands Leadership Team with Appointment of James M. O’Brien as Chief Financial Officer

PITTSBURGH, November 4, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that James M. O’Brien has joined the Company as chief financ…

Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting

PITTSBURGH, October 15, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Fourth International Symposium on Sig…

Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting

PITTSBURGH, October 10, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the Company would be presenting three posters on Elayta…
Show more

Cognition Therapeutics Frequently Asked Questions

  • When was Cognition Therapeutics founded?

    Cognition Therapeutics was founded in 2007.

  • Who are Cognition Therapeutics key executives?

    Cognition Therapeutics's key executives are Lisa Ricciardi, James M. O'Brien and Brett P. Monia.

  • How many employees does Cognition Therapeutics have?

    Cognition Therapeutics has 18 employees.

  • Who are Cognition Therapeutics competitors?

    Competitors of Cognition Therapeutics include Boston Analytical, Cellarity and Bioiberica.

  • Where is Cognition Therapeutics headquarters?

    Cognition Therapeutics headquarters is located at 2403 Sidney Street, Pittsburgh.

  • Where are Cognition Therapeutics offices?

    Cognition Therapeutics has offices in Pittsburgh and Harrison.

  • How many offices does Cognition Therapeutics have?

    Cognition Therapeutics has 2 offices.